Endovia Health Sciences Stock Jumps 48% After Hours - Endovia Health Sciences (AMEX:EDVA)

Endovia Health Sciences (EDVA) announced FDA's determination that CannEpil qualifies as a minor use for canine bone cancer pain, enabling a conditional approval pathway. The company plans to meet with the FDA in November 2026 to discuss studies and regulatory submissions, aiming for a potential 2027 launch, subject to approvals.

Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway Companies to Meet Formally with FDA’s Center for Veterinary Medicine on Novembe

Endovia Health Sciences (EDVA) received FDA minor-use status for CannEpil, a treatment for canine bone cancer pain, enabling a conditional approval pathway. The company will meet with the FDA on Nov. 19 and plans U.S. manufacturing for a potential 2027 launch, pending approvals.

Endovia Health Sciences (EDVA) and Lupvindol BioSciences announced that the FDA determined CannEpil, a CBD/THC oral solution for canine bone cancer pain, qualifies for the MUMS program, enabling a conditional approval pathway. The companies plan to meet with the FDA in November and aim for a potential 2027 commercial launch, pending regulatory approval and manufacturing readiness.

Worthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.

Minerals Technologies (MTX) completed a $400 million offering of 7.50% Senior Notes due 2032 to refinance 2028 debt and expanded its revolving credit facility to $500 million, maturing in 2031. The moves aim to strengthen liquidity and extend debt maturities, according to the company.